Immunologic Factors: all 3,292 studies that test it
Page 17 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.
- Therapies for Down Syndrome Regression DisorderCompletedNCT05662228Phase 2
- Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell LymphomaTerminatedNCT05660967Phase 2
- A Randomized Controlled Trial With Rituximab for Psychotic Disorder in AdultsActive, not recruitingNCT05622201Phase 2
- Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)CompletedNCT05618301Phase 1
- Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell LymphomaActive, not recruitingNCT05600686Phase 2
- A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)TerminatedNCT05600426Phase 3
- Immunomodulators on HIV-1 ReservoirStatus unknownNCT05598580Phase 4
- Immunomodulatory Therapy in Women With Autoimmune Premature Ovarian InsufficiencyCompletedNCT05586737Phase 2
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Phase 3
- Study of Teclistamab in Combination in Elderly Patients With Multiple MyelomaActive, not recruitingNCT05572229Phase 2
- A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After TreatmentActive, not recruitingNCT05556798Phase 1
- Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative StudyCompletedNCT05555329Phase 4
- A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular LymphomaActive, not recruitingNCT05551936Phase 1/2
- Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)Status unknownNCT05549284Phase 2
- Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR RelapseActive, not recruitingNCT05533164Phase 3
- Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently DiagnosedCompletedNCT05533125Phase 3
- A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedNCT05532163Phase 4
- Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and DexamethasoneStatus unknownNCT05509374Phase 2
- Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH TrialActive, not recruitingNCT05497804Phase 2
- A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell LymphomaActive, not recruitingNCT05495464Early Phase 1
- Lenalidomide in the Treatment of Refractory Cutaneous DermatomyositisStatus unknownNCT05488327Not applicable
- Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple SclerosisWithdrawnNCT05482542Not applicable
- Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down SyndromeWithdrawnNCT05482334Phase 2
- Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT05457556Phase 3
- Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell LymphomaActive, not recruitingNCT05455697Phase 1/2
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Phase 3
- Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic LeukemiaActive, not recruitingNCT05453500Phase 2
- PVd Versus Vd in NDMM Patients With RIStatus unknownNCT05432414Phase 2
- Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)Active, not recruitingNCT05429268Phase 3
- RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSLStatus unknownNCT05425654Phase 2
- Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMMWithdrawnNCT05408026Phase 1/2
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)Active, not recruitingNCT05406401Phase 2
- R-MTX-zanbrutinib in Secondary CNS LymphomaStatus unknownNCT05398224Phase 2
- Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical TrialStatus unknownNCT05392257Phase 2
- Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by InhalationCompletedNCT05366283Phase 1
- A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell LymphomaCompletedNCT05364424Phase 1
- GPL in Patients with Relapsed/refractory Diffuse Large B Cell LymphomaActive, not recruitingNCT05335018Phase 2
- Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia GravisStatus unknownNCT05332587Phase 3
- Evaluation of Glucocorticoids Plus Rituximab in Patients With Newly-Diagnosed or Relapsing IgA VasculitisCompletedNCT05329090Phase 3
- B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple SclerosisActive, not recruitingNCT05296161Phase 4
- Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic DisordersWithdrawnNCT05293509Phase 2
- Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLLStatus unknownNCT05287984Phase 2
- Ocrelizumab Discontinuation in Relapsing Multiple SclerosisActive, not recruitingNCT05285891Phase 4
- Sargramostim With Ipilimumab Containing Therapy in Patients With Solid TumorsWithdrawnNCT05284214Phase 2
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple SclerosisActive, not recruitingNCT05269004Phase 3
- A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHLTerminatedNCT05265975Phase 1/2
- A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05236621Phase 3
- Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCTStatus unknownNCT05214066Phase 2
- LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMABActive, not recruitingNCT05210621Phase 3
- Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLLWithdrawnNCT05209308Phase 2
- A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple SclerosisWithdrawnNCT05208840Phase 4
- A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.WithdrawnNCT05205252Phase 1/2
- A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell LymphomaStatus unknownNCT05200312Phase 2
- Antithymocyte Globulin as a Second Line Therapy in Graves OrbitopathyStatus unknownNCT05199103Not applicable
- Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid StudyStatus unknownNCT05191225Phase 4
- A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple MyelomaWithdrawnNCT05183139Phase 4
- Phase III Clinical Study of NPB-01 in Patients With Autoimmune EncephalitisStatus unknownNCT05177939Phase 3
- BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)Active, not recruitingNCT05156710Phase 2
- A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal ImpairmentStatus unknownNCT05147493Phase 2
- A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus ErythematosusTerminatedNCT05140824Phase 1
- Effect of Pre-emptive Intravenous Immunoglobulin (IVIG) on the Incidence of Septic Episodes in Pediatric Burn PatientsCompletedNCT05134792Phase 2/3
- Isa-RVD Study in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT05123131Phase 2
- Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell LymphomasTerminatedNCT05105412Phase 1/2
- IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome PatientsCompletedNCT05104762Phase 2/3
- A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaActive, not recruitingNCT05100862Phase 3
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Phase 3
- Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple SclerosisStatus unknownNCT05078177Phase 1
- Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell LymphomaCompletedNCT05058755Not applicable
- Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus ErythematosusStatus unknownNCT05057481Phase 3
- Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT05052528Phase 1
- Marizomib Central Nervous System (CNS)WithdrawnNCT05050305Phase 2
- Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.Status unknownNCT05049473Phase 2
- A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSLCompletedNCT05036577Phase 1
- ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin LymphomaActive, not recruitingNCT05025800Phase 1/2
- Felzartamab in Late Antibody-Mediated RejectionCompletedNCT05021484Phase 2
- Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell LymphomaStatus unknownNCT05014100Phase 2
- Acalabrutinib and Rituximab in Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT05004064Phase 2
- Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop StudyActive, not recruitingNCT04978584Phase 2
- A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)WithdrawnNCT04974996Phase 1
- Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or OlderActive, not recruitingNCT04974216Phase 2
- Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple SclerosisCompletedNCT04966338Phase 3
- Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)Active, not recruitingNCT04944979Phase 3
- Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)Active, not recruitingNCT04936282Phase 4
- Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System LymphomaCompletedNCT04934579Phase 2
- Lenalidomide and Dexamethasone for Rosai-Dorfman DiseaseStatus unknownNCT04924647Phase 2
- Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRLStatus unknownNCT04899453Phase 2
- Daratumumab and Pomalidomide in Previously Treated Patients With AL AmyloidosisTerminatedNCT04895917Phase 2
- MOR202 for Refractory MNCompletedNCT04893096Phase 2
- Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04883242Phase 2
- Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell LymphomaWithdrawnNCT04882163Phase 1/2
- Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell TransplantActive, not recruitingNCT04876248Phase 2
- Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute LeukemiaActive, not recruitingNCT04872790Phase 1
- TReatment for ImmUne Mediated PathopHysiologyActive, not recruitingNCT04862221Phase 2
- Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04850599Phase 2
- Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY)CompletedNCT04826588Phase 3
- Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsActive, not recruitingNCT04824092Phase 3
- Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCLStatus unknownNCT04796857Phase 1/2
- A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT04790903Phase 1
- Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic SyndromeCompletedNCT04783675Phase 2
- Study of Selinexor Plus DRd for Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04782687Phase 2